Although PD-1/PD-L1 axis-targeting immune checkpoint inhibitor (ICI) has revolutionized the therapeutic modality of several types of cancers, an obvious fraction of cancer patients showed no responses to ICI monotherapy (1, 2). The gene discussed is CD274; the disease is cancer.